Florida, Texas turn to COVID-19 antibody treatments amid new surges

Doctors are increasingly turning to antibody drugs in a bid to keep hospitals from being overwhelmed by a surge of COVID-19 cases, a turnabout after months in which the treatments went mostly unused.

Regeneron estimates that as recently as June, fewer than 5% of high-risk patients were receiving treatment, before increasing recently to as much as 30%, said Chief Executive Leonard Schleifer in an interview. The drugs, which have been shown to prevent hospitalizations, are paid for by the federal government, and distributed to patients free of charge. In January 2021, the federal government agreed to pay $2.63 billion for 1.25 million doses, equivalent to $2,100 per dose of Regeneron’s drug, which is a cocktail of two antibodies. The contract followed a previous agreement in July 2020 in which the U.S. paid $450 million for 300,000 doses.